JP2021523946A5 - - Google Patents

Info

Publication number
JP2021523946A5
JP2021523946A5 JP2021514457A JP2021514457A JP2021523946A5 JP 2021523946 A5 JP2021523946 A5 JP 2021523946A5 JP 2021514457 A JP2021514457 A JP 2021514457A JP 2021514457 A JP2021514457 A JP 2021514457A JP 2021523946 A5 JP2021523946 A5 JP 2021523946A5
Authority
JP
Japan
Prior art keywords
lck
amino acid
composition according
composition
optionally
Prior art date
Application number
JP2021514457A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019218016A5 (https=
JP2021523946A (ja
JP7386852B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050463 external-priority patent/WO2019218016A1/en
Publication of JP2021523946A publication Critical patent/JP2021523946A/ja
Publication of JPWO2019218016A5 publication Critical patent/JPWO2019218016A5/ja
Publication of JP2021523946A5 publication Critical patent/JP2021523946A5/ja
Application granted granted Critical
Publication of JP7386852B2 publication Critical patent/JP7386852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514457A 2018-05-15 2019-05-15 ペプチド活性化剤 Active JP7386852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901673 2018-05-15
AU2018901673A AU2018901673A0 (en) 2018-05-15 Peptide Activating Agent
PCT/AU2019/050463 WO2019218016A1 (en) 2018-05-15 2019-05-15 Peptide activating agent

Publications (4)

Publication Number Publication Date
JP2021523946A JP2021523946A (ja) 2021-09-09
JPWO2019218016A5 JPWO2019218016A5 (https=) 2022-05-24
JP2021523946A5 true JP2021523946A5 (https=) 2022-05-24
JP7386852B2 JP7386852B2 (ja) 2023-11-27

Family

ID=68539135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514457A Active JP7386852B2 (ja) 2018-05-15 2019-05-15 ペプチド活性化剤

Country Status (8)

Country Link
US (2) US11912789B2 (https=)
EP (1) EP3794014A4 (https=)
JP (1) JP7386852B2 (https=)
KR (1) KR102918269B1 (https=)
CN (1) CN112399970B (https=)
AU (1) AU2019268412B2 (https=)
CA (1) CA3100074A1 (https=)
WO (1) WO2019218016A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518187B (zh) * 2020-04-16 2022-05-10 中国农业科学院饲料研究所 抗菌肽dn6nh2及其应用
JP2024532850A (ja) * 2021-08-20 2024-09-10 インテルク ペプチド セラピューティクス リミテッド がん及びがん療法に関連する自己免疫を含む、自己免疫を処置するための組成物及び方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
AU2005204275B2 (en) * 1999-06-28 2008-10-16 Inter-K Pty Limited A method of modulating integrin mediated cellular activity and agents useful for same
AU2007231835A1 (en) * 2000-12-22 2007-11-29 Inter-K Pty Limited Screening assay for an inhibitor of MAP kinase?integrin binding
JP2007522094A (ja) * 2003-09-22 2007-08-09 アシドフィル エルエルシー 小分子組成物、及びその組成物を使用して薬物効率を高めるための方法
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
CN101854945B (zh) * 2007-09-18 2015-07-01 株式会社绿多肽 Ctl诱导剂组合物
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
EP2378875B1 (en) 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2010094085A1 (en) * 2009-02-23 2010-08-26 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20120277161A1 (en) * 2009-02-23 2012-11-01 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20110200560A1 (en) * 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2012033911A2 (en) * 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
BR112013026199A2 (pt) * 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
US20140186372A1 (en) 2011-06-16 2014-07-03 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
US9403877B2 (en) * 2012-01-24 2016-08-02 Inter-K Pty Limited Peptide agents for cancer therapy
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN112368293A (zh) 2018-05-15 2021-02-12 英特肽治疗有限公司 活化剂

Similar Documents

Publication Publication Date Title
JP7360419B2 (ja) 安定化抗微生物性ペプチド
JP2021523945A5 (https=)
Mercer et al. Peptides as the next generation of anti-infectives
JP2014521684A5 (https=)
JP2013500990A5 (https=)
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
JP2008514586A5 (https=)
CA2112907C (en) Peptide which abrogates tnf and/or lps toxicity
JP2005526833A5 (https=)
RU2016110153A (ru) Новые пептиды и их аналоги для применения при лечении мукозита полости рта
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2021523946A5 (https=)
US20250215054A1 (en) Compositions and methods for treatment of fungal infections
JP2009534451A5 (https=)
JPWO2022202816A5 (https=)
JPWO2019218015A5 (https=)
JPWO2019218016A5 (https=)
JP2006523608A5 (https=)
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
EP2990415B1 (en) Cyclic beta defensins analogs for the treatment of infections
JP2015514771A5 (https=)
JPWO2018038168A1 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
US12012440B2 (en) Compositions and methods for treatment of fungal infections
JP2009515933A (ja) インフルエンザにおけるインターフェロン
WO1997048725A1 (en) Novel peptides for prevention and treatment of infection